Regeneron Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Regeneron Pharmaceuticals, Inc.
Traded as
IndustryPharmaceuticals; Biotech
HeadquartersEastview, New York, US (Headquarters)
Area served
Key people
RevenueIncrease $5.87 billion (2017)[1]
Increase $1.4 billion[1]
Total assetsIncrease $5.6 billion[1]
Number of employees
6,200[2] (2017)

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988.[3] Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

Company history[edit]

Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.

On March 26, 2012, Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. The new drug targets the PCSK9 gene.[4][citation needed]

In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[5] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[6] REGN2810 was later named cemiplimab.

Marketed products[edit]

ARCALYST (rilonacept) for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.

EYLEA (aflibercept injection) Approved by the U.S. Food and Drug Administration (FDA) in November 2011.[3][7] EYLEA developed to treat a common cause of blindness in the elderly. EYLEA is reported to cost $11,000 per year for each eye treated.[8]

ZALTRAP (aflibercept injection) for metastatic colorectal cancer: Approved by the FDA in August 2012.[9]

PRALUENT (alirocumab) indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by FDA on 24 July 2015 [10] It is reported to cost $4,500 to $8,000 per year.[11]

DUPIXENT (dupilumab injection) is for the treatment of adolescent and adult patients' atopic dermatitis. Approved by FDA on 28 March 2017.[12] It is reported to cost $37,000 per year.[8]

KEVZARA (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment of adult patients with rheumatoid arthritis. Approved by FDA on 22 May 2017.[13]

LIBTAYO (cemiplimab injection) is a monoclonal antibody targeting the PD-1 pathway as a checkpoint inhibitor, for the treatment of patients with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Approved by FDA on 28 September 2018.[14]

Technology platforms[edit]

Trap Fusion Proteins: Regeneron’s novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.

Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.[15]:255–258

Financial performance[edit]

Financial Year Revenue Ref
2012 $1.4 billion [16]
2013 $2.1 billion [16]
2014 $2.8 billion [1]
2015 $4.1 billion [1]
2016 $4.8 billion [1]
2017 $5.8 billion [1]
2018 $6.7 billion [1]

Key people[edit]

The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos. They are reported to hold $1.3 billion and $900 million in company stock, respectively. Both are from Queens, New York.[8]

Schleifer was formerly a professor of medicine at Weill Cornell Medical School. Yancopoulos was an assistant professor at Columbia University. Yancopoulos was involved in each drug's development.[8]

See also[edit]


  1. ^ a b c d e f g h [1][dead link]
  2. ^ "Regeneron Pharmaceuticals". Fortune. Retrieved 2018-12-31.
  3. ^ a b Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. United States. Archived from the original on March 16, 2014. Retrieved March 22, 2014. Cite uses deprecated parameter |deadurl= (help)open access
  4. ^ Husten, Larry. "Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race". Forbes. Retrieved 2018-02-22.
  5. ^ "Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration - GEN News Highlights - GEN".
  6. ^ "UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology - FierceBiotech".
  7. ^ "Regulators Approve a Drug for an Eye Condition". The New York Times. Associated Press. November 18, 2011.(registration required)
  8. ^ a b c d "Regeneron's Billionaire Founder Battles The Drug Pricing System". Forbes. 26 July 2018. Retrieved 26 July 2018.
  9. ^ "FDA approves Zaltrap for metastatic colorectal cancer" (Press release). U.S. Food and Drug Administration. August 3, 2012. Archived from the original on June 25, 2013. Cite uses deprecated parameter |deadurl= (help)
  10. ^ "Archived copy". Archived from the original on 2015-07-27. Retrieved 2015-07-29. Cite uses deprecated parameter |dead-url= (help)CS1 maint: archived copy as title (link)
  11. ^ Tirrell, Meg (2018-05-01). "A $14,000 cholesterol drug gets a price cut as Regeneron, Sanofi strike deal with Express Scripts". CNBC. Retrieved 2018-08-22.
  12. ^ Inc., Regeneron Pharmaceuticals,. "Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis". maint: extra punctuation (link)
  13. ^ "Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (NASDAQ:REGN)".
  14. ^ "FDA approves first treatment for advanced form of the second most common skin cancer (NASDAQ:REGN)".
  15. ^ Susana Magadán Mompó and África González-Fernández. Human Monoclonal Antibodies from Transgenic Mice. Chapter 13 in Human Monoclonal Antibodies: Methods and Protocols Ed. Michael Steinitz. Springer Science+Business Media, 2014. ISBN 978-1-62703-585-9
  16. ^ a b "REGENERON PHARMACEUTICALS INC 2013 Annual Report Form (10-K)" (XBRL). United States Securities and Exchange Commission. February 13, 2014.

External links[edit]